Saturday 7 November 2026 Export MCRB’s income statement to Excel — free account

Seres Therapeutics, Inc.

Seres Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $789,000.00, down 99.4% from fiscal 2023.

Revenue: +69.0%
EPS: −273.6%
Free cash flow: −576.7%

Quarter to September 2026, against a year earlier

1.97 0.12 −5.74%

Follow MCRB

Alert me

Market cap: $20.8M
P/E: 0.0×
Fwd P/E: −0.6×
Dividend yield: —
F-score: n/a
Altman Z: −10.99
Beneish M: n/a
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Sold, $m 0.01

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	4	—	—	4	—	—	4	—	—	—

Insider Ownership 23.86%

Capital & Financial Ratios $m

Size

Market Cap 20.78

Revenue ttm 2.13

Net income ttm (46.95)

Free cash flow ttm (63.70)

Net debt Q (17.53)

Valuation

P/E 0.00

Forward P/E (0.56)

Price / sales 9.25

Forward P/S Powerpack

Price / FCF 0.00

Price / book 0.92

Financial health

Current ratio Q 1.65

Debt / equity Q 0.00

Interest coverage Q (8.38)

Growth

Revenue growth Q +68.95%

Operating income growth Q +28.14%

EPS, this year −699.79%

EPS, next year A +34.99%

Revenue, next year A +1,649.05%

EPS, past 5 yrs —

EPS, next 5 yrs A +25.41%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 50.61%

10-year low 10-year high

P/B against its own 10 years 0.38%

10-year low 10-year high

EV/Sales against its own 10 years 77.18%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	128	31	46	18
Receivables	9	2	1	13
Inventory	—	—	—	—
Other	—	—	—	—
	175	39	49	34

	2023	2024	2025	Q'26
Payables	4	4	2	1
ST’ Debt	—	—	—	—
Other	—	—	—	—
	99	41	19	21

Compound Annual Growth %

	10y	5y	3y
Sales	—	(53.03%)	(82.41%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(14.24%)	(24.03%)	60.06%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −1.34 Actual −1.06

−2.89 −1.81 −0.73 0.36 1.44

Q3 FY25 Beat +0.89

Q4 FY25 Beat +0.50

Q2 FY26 Beat +0.57

Q3 FY26 Beat +0.28

Q4 FY26 — Mar 11

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q3 FY25	0.05	0.94	Beat by 0.89
Q4 FY25	−2.39	−1.89	Beat by 0.50
Q2 FY26	−2.07	−1.50	Beat by 0.57
Q3 FY26	−1.34	−1.06	Beat by 0.28
Q4 FY26	−1.56	—	Reports 11 March 2027

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(2.08)	0.47	(1.63)	—	—
’25	3.75	(2.27)	0.94	(1.76)	0.64
’24	(5.40)	(4.40)	11.60	(1.78)	0.00
’23	(11.40)	7.20	(7.40)	(6.40)	(17.80)
’22	(12.20)	(14.00)	(9.80)	(10.80)	(46.20)
’21	(7.80)	(10.60)	14.40	(11.00)	(14.40)
’20	(5.60)	(5.60)	(7.20)	(3.60)	(22.40)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	1	1	—	—
’25	—	—	0	0	1
’23	(1)	126	0	0	126
’22	1	1	3	1	7
’21	6	5	127	7	145
’20	8	6	1	18	33
’19	7	13	7	8	35

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(16)	(22)	(10)	—	—
’25	27	(13)	2	(15)	1
’24	(35)	(40)	(35)	(39)	(149)
’23	(77)	66	(59)	(47)	(117)
’22	(66)	(50)	(60)	(53)	(229)
’21	(29)	(40)	128	(52)	7
’20	(24)	(26)	(26)	(18)	(94)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(16)	(22)	(10)	—	—
’25	27	(13)	2	(15)	1
’24	(35)	(40)	(35)	(39)	(149)
’23	(81)	65	(61)	(48)	(125)
’22	(69)	(52)	(61)	(56)	(239)
’21	(31)	(42)	124	(53)	(3)
’20	(24)	(26)	(26)	(18)	(94)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Sep ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	22	32	28	35	33	145	7	126	—	1	2		(30.8%)	14	0	0	(29.8%)
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	—	100.00	100.00		0.0 pt	Powerpack Seres Therapeutics, Inc.’s next three years, line by line Analysts expect revenue to shrink 29.8% a year to 2028 — faster than the −30.8% of the last 9 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(92)	(89)	(99)	(70)	(89)	(66)	(184)	(190)	(126)	6	(47)		n/m
	EBT margin, %	(420.74)	(278.44)	(350.03)	(203.68)	(268.33)	(45.25)	(2,575.49)	(150.51)	0.00	721.93	(2,209.55)		+1,142.7 pt
	Net income	(92)	(89)	(99)	(70)	(89)	(66)	(250)	(114)	0	6	(47)		n/m
Per share, $
Per share, $	Revenue	10.92	15.87	13.88	12.18	8.33	31.61	1.32	19.74	0.00	0.09	0.21		(41.4%)
	Earnings	(46.00)	(44.20)	(48.60)	(24.80)	(22.40)	(14.40)	(46.20)	(17.80)	0.00	0.64	(5.00)		n/m
	Cash flow	22.04	(37.34)	(30.85)	(27.01)	(23.46)	1.46	(42.34)	(18.34)	(19.13)	0.13	(6.41)		(43.7%)
	Capex	(10.79)	(2.31)	(0.95)	(0.35)	(0.15)	(2.09)	(1.82)	(1.25)	(0.05)	0.00	0.02		(57.7%)
	Free cash flow	11.26	(39.65)	(31.80)	(27.37)	(23.61)	(0.63)	(44.16)	(19.58)	(19.17)	0.12	(6.38)		(39.6%)
	Book value	66.57	30.01	(23.58)	(17.06)	43.80	28.68	2.00	(7.01)	1.77	4.99	2.14		(25.0%)
	Shares, m	2	2	2	3	4	5	5	6	8	9	10		+18.0%
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	22.21	0.00		2.5
	P/S	18.33	13.29	6.52	5.66	58.85	5.27	81.88	1.42	—	89.49	9.25		31.2
	P/B	3.01	7.03	0.00	0.00	11.19	5.81	54.12	0.00	—	2.98	0.92		9.3
	EV/Sales	9.94	8.90	3.72	3.63	51.96	3.44	63.53	1.21	—	128.00	49.24		30.5
	EV/FCF	9.65	(3.56)	(1.62)	(1.62)	(18.32)	(172.98)	(1.90)	(1.22)	—	175.40	(1.64)		(1.8)
Cash, $m
Cash, $m	Operating cash flow	44	(76)	(63)	(77)	(94)	7	(229)	(117)	(149)	1	(64)		(33.5%)
	Capex	(21)	(5)	(2)	(1)	(1)	(10)	(10)	(8)	0	0	0		(50.0%)
	Free cash flow	22	(80)	(65)	(78)	(94)	(3)	(239)	(125)	(149)	1	(64)		(28.6%)
Balance, $m
Balance, $m	Working capital	168	123	51	54	222	221	109	77	(3)	30	14		(17.4%)
	Net debt	(183)	(141)	(79)	(70)	(229)	(266)	(131)	(26)	(31)	(46)	(18)		(14.2%)
	Shareholders’ equity	133	61	(48)	(48)	175	132	11	(45)	14	44	21		(11.5%)
Returns, %
Returns, %	ROA	(37.41)	(38.68)	(63.83)	(55.58)	(37.50)	(18.80)	(71.10)	(32.15)	0.05	4.10	(44.85)		+41.5 pt
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	(1,267.77)		0.0 pt
	ROE	(54.18)	(92.46)	(1,563.81)	145.85	(140.99)	(42.83)	(351.62)	667.53	(0.88)	19.64	(144.35)		+73.8 pt
People
People	Employees	127	138	145	108	155	333	431	160	103	66	—		(7.0%)
	Revenue/emp, $m	0.17	0.23	0.19	0.32	0.21	0.44	0.02	0.79	0.00	0.01	—		(25.6%)

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 6 Nov 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
EVAX Evaxion A/S - Sponsored ADR	$23.0M	— (loss-making)	— (loss-making)	+14,590.20% (above 0%: growing)	n/m	−56.70% (below 0%: shrinking)	100.00%	0.00%	Compare
IGC IGC Pharma, Inc.	$22.0M	— (loss-making)	— (loss-making)	0.00%	n/m	−45.33% (below 0%: shrinking)	18.60%	(588.72%)	Compare
CRVO CervoMed Inc.	$21.9M	— (loss-making)	— (loss-making)	−99.60% (below 0%: shrinking)	n/m	−6.20% (below 0%: shrinking)	100.00%	0.00%	Compare
FLNA Cassava Sciences, Inc.	$21.8M	— (loss-making)	—	+1,328.04% (above 0%: growing)	n/m	+21.65% (above 0%: growing)	0.00%	0.00%	Compare
MCRB Seres Therapeutics, Inc.	$20.8M	— (loss-making)	— (loss-making)	+68.95% (above 0%: growing)	n/m	−576.66% (below 0%: shrinking)	100.00%	(2,723.78%)
ATOS Atossa Therapeutics, Inc.	$20.2M	— (loss-making)	—	−94.28% (below 0%: shrinking)	n/m	−32.86% (below 0%: shrinking)	0.00%	0.00%	Compare
IMMP Prima BioMed Ltd	$19.8M	—	—	—	n/m	−589,653.13% (below 0%: shrinking)	100.00%	(101.89%)	Compare
BSEM BioStem Technologies, Inc.	$19.4M	— (loss-making)	— (loss-making)	−27.95% (below 0%: shrinking)	n/m	—	61.28%	(106.35%)	Compare
COCP Cocrystal Pharma, Inc.	$19.3M	— (loss-making)	— (loss-making)	−81.05% (below 0%: shrinking)	n/m	−16.75% (below 0%: shrinking)	100.00%	(3,032.38%)	Compare
Median of peers	$21.0M	—	—	−27.95%	—	−32.86%	80.64%	(50.94%)

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 27 April 2026

Ownership

Directors and executive officers, together 5.20%

Entities affiliated with Flagship Pioneering 12.00%

Nestlé S.A. 11.30%

Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Seres Therapeutics, Inc. (MCRB) Latest News

4 Nov

Impact 3 · 7:00 AM · GlobeNewswire

Seres Therapeutics Reports Third Quarter 2026 Financial Results and Announces Plans for Advancing Development of SER-155 To Prevent Immune Checkpoint Inhibitor-Related Enterocolitis (irEC)

3 Nov

Impact 3 · 7:00 AM · GlobeNewswire

Seres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine Showing Reduced Bloodstream Infections in Allogeneic Hematopoietic Cell Transplantation Recipients

15 Oct

Impact 3 · 7:00 AM · GlobeNewswire

Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026

5 Aug

Impact 3 · 7:00 AM

Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs

10 Jul

Impact 4 · 2:02 PM · MarketBeat

Seres Therapeutics’ SER-155 Posts 80% Response in Cancer Immunotherapy GI Toxicity Study

8 Jul

Impact 4 · 7:00 AM

Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment

13 Jun

Impact 3 · 8:57 AM

We're A Little Worried About Seres Therapeutics' (NASDAQ:MCRB) Cash Burn Rate

5 Jun

Impact 4 · 7:00 AM · GlobeNewswire

Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027

5 May

Impact 3 · 7:00 AM · GlobeNewswire

Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

20 Apr

Impact 3 · 7:00 AM

Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026

Impact 3 · 7:00 AM

Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026

12 Mar

Impact 4 · 7:23 AM · Associated Press Finance

Seres Therapeutics: Q4 Earnings Snapshot

Impact 4 · 7:00 AM · GlobeNewswire

Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

2 Mar

Impact 4 · 4:05 PM · GlobeNewswire

Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates

12 Feb

Impact 4 · 7:00 AM · biopharmadive.com

Seres to lay off staff, pause top program in latest reboot

Impact 4 · 7:00 AM · GlobeNewswire

Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases

6 Jan

Impact 4 · 7:00 AM · GlobeNewswireZacksMT NewswiresMT NewswiresMT NewswiresMT NewswiresMotley FoolMT Newswires

Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy

29 Dec

Impact 3 · 10:15 AM · Zacks

3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround

5 Nov

Impact 3 · 7:00 AM · GlobeNewswire

Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

29 Oct

Impact 4 · 7:00 AM · GlobeNewswire

Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155

14 Oct

Impact 4 · 7:00 AM · GlobeNewswireMT NewswiresPharmaceutical TechnologyMT NewswiresClinical Trials ArenaClinical Trials Arena

Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant

23 Sep

Impact 3 · 7:00 AM · GlobeNewswire

Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway

9 Sep

Impact 4 · 12:00 PM

All You Need to Know About Seres Therapeutics (MCRB) Rating Upgrade to Buy

28 Aug

Impact 4 · 9:55 AM · Zacks

Seres Therapeutics (MCRB)'s Technical Outlook is Bright After Key Golden Cross

6 Aug

Impact 4 · 7:00 AM · GlobeNewswire

Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

Impact 3 · 7:15 AM · Associated Press Finance

Seres Therapeutics: Q2 Earnings Snapshot

22 Jul

Impact 4 · 7:00 AM · GlobeNewswire

Seres Therapeutics Announces Leadership Transition

21 Jul

Impact 3 · 11:51 AM · Simply Wall St.

Seres Therapeutics, Inc.'s (NASDAQ:MCRB) top owners are individual investors with 51% stake, while 23% is held by institutions

27 May

Impact 4 · 7:00 AM

Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting

23 May

Impact 4 · 12:00 PM · Zacks

Seres Therapeutics (MCRB) Upgraded to Buy: What Does It Mean for the Stock?

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Seres Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 27 April 2026

Ownership

Seres Therapeutics, Inc. (MCRB) Latest News

4 Nov

3 Nov

15 Oct

5 Aug

10 Jul

8 Jul

13 Jun

5 Jun

5 May

20 Apr

12 Mar

2 Mar

12 Feb

6 Jan

29 Dec

5 Nov

29 Oct

14 Oct

23 Sep

9 Sep

28 Aug

6 Aug

22 Jul

21 Jul

27 May

23 May

Stockrow Weekly